- The stock price of Geovax Labs Inc (NASDAQ: GOVX) increased by over 10% during intraday trading. This is why it happened.
The stock price of Geovax Labs Inc (NASDAQ: GOVX) – a biotechnology company specializing in developing human vaccines – increased by over 10% during intraday trading. Investors are responding positively to GeoVax Labs announcing the presentation of data from a study of its preventive vaccine against Sudan Ebolavirus (SUDV).
The presentation — titled “A single immunization of guinea pigs with a modified vaccinia Ankara virus-producing Sudan virus-like particles protects from Sudan virus lethal challenge” — was delivered by Dr. Delphine Malherbe of the Bukreyev Lab, Department of Pathology, University of Texas Medical Branch, Galveston, Texas during the Annual Meeting of the American Society for Virology, being held virtually July 19-23.
In the talk, Dr. Malherbe discussed the preclinical efficacy studies of GeoVax’s vaccine (MVA-SUDV-VLP), a novel vaccine candidate for SUDV constructed on an MVA vector expressing two immunogens (GP and VP40) derived from the Sudan virus. And upon vaccination, these immunogens form Virus Like Particles (VLPs) in the host — which in turn induce immunity against subsequent infections with SUDV. Immunogenicity and efficacy of MVA-SUDV-VLP were tested in a guinea pig lethal challenge model in which a single intramuscular dose of the GeoVax vaccine protected 100% of animals challenged with a lethal dose of SUDV.
A comparison between prime and prime-boost vaccinations of guinea pigs with MVA-SUDV-VLP showed that both regimens had elicited SUDV-specific binding and neutralizing antibody responses and that the second immunization enhanced these responses. The challenge of vaccinated animals with guinea pig-adapted SUDV demonstrated a complete protection against death and disease by the prime and the prime-boost regimens. There was no difference in outcomes between the prime and the prime-boost vaccine regimens thus demonstrating the efficacy of a single dose of MVA-SUDV-VLP. And this is the first report that a replication-deficient MVA vector may confer full protection against SUDV after a single dose.
“The level of protection against Sudan virus we observed was remarkable.”
— Alexander Bukreyev, PhD, Professor, Department of Pathology, University of Texas Medical Branch, Galveston, Texas
“The presentation of data from this study further validates our platform and approach to addressing Sudan virus, and we look forward to advancing our vaccine to non-human primate testing. Previously, our novel vaccine against Ebola virus achieved 100% single-dose protection in a nonhuman primate lethal challenge model and we have consistently validated our vaccine platform capability against other infectious pathogens, resulting in vaccine candidates that have demonstrated 100% preclinical protection in a single dose, without the need for adjuvants. Such attributes are critically important when developing vaccines against emergent epidemic threats.”
— David Dodd, GeoVax President and CEO
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.